China SXT Pharmaceuticals, Inc. SXTC
China SXT Pharmaceuticals, Inc. statistics & valuation
Market cap$92.5M
P / S81.3×
P / B3.1×
Net margin-545.2%
Return on equity-20.9%
Net cash$27.5M
Enterprise value USD$65.0M
Earnings yield EBIT/EV-11%
Return on capital-23.4%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 21.9% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% | 48.5% |
| Operating margin | -625.9% | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% | -26.0% | 25.2% | 23.3% |
| Net margin | -545.2% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 22.0% | 16.9% |
| FCF margin | — | -134.8% | -100.3% | — | — | — | 15.6% | -4.2% | 21.1% |
| Return on assets | -17.9% | -15.2% | -13.4% | -20.1% | -17.1% | -8.0% | -47.4% | 8.8% | 15.5% |
| Return on equity | -20.9% | -21.4% | -22.2% | -40.4% | -35.7% | -17.2% | -109.4% | 13.9% | 36.1% |
| Debt / equity | 0.02× | 0.38× | 0.33× | 0.01× | — | 0.00× | 0.00× | 0.00× | — |
| Current ratio | 7.93 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 |
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.